Skip to content

Effects and Safety of Simvastatin Ointment in the Treatment of Congenital Ichthyosis

Effects and Safety of Simvastatin Ointment in the Treatment of Congenital Ichthyosis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037278
Enrollment
Unknown
Registered
2020-08-27
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inherited ichthyosis

Interventions

ARCI group:Concentration of simvastatin cream
XLI group:Concentration of simvastatin cream

Sponsors

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The subject is clinically, pathologically and genetically diagnosed as juvenile congenital ichthyosis (autosomal recessive or X-linked). 2. The subject is of stable vital signs. 3. The subject or guardian agrees to participate in the study and signs the informed consent. 4. There is no restriction on age or gender.

Exclusion criteria

Exclusion criteria: 1. Patients who have serious allergy or infection in the skin lesions; 2. Patients who are allergic to the drugs used in this study; 3. Patients who used oral lipid-lowering drugs in recent three months; 4. Patients who had oral retinoids in recent three months; 5. Patients who had oral hormone or other immunosuppressive drugs in recent three months; 6. Patients with precancerous skin damage; 7. Patients with severe heart, liver or renal insufficiency; 8. Patients with chronic infection such as HIV, HBV and HCV; 9. Lactating women, pregnant women or patients with potential pregnancy during treatment and refusing contraception; 10. Those who can't insist on treatment; 11. Patients enrolled in any other clinical trials.

Design outcomes

Primary

MeasureTime frame
thickness of skin lesion / desquamation degree;discomfort such as pain or itching;Erythema;influence on daily life;histopathology and electron microscope;Immunohistochemistry;mRNA and protein levels of defective genes;

Secondary

MeasureTime frame
compete blood count;urinalysis;serum lipid metabolism;liver function and renal function;myocardial enzymogram;EKG;X-ray;abdominal ultrasound;

Countries

China

Contacts

Public ContactZhirong Yao

Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine

yaozhirong@xinhuamed.com.cn+86 13651652986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026